Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension.

导出 LinkOut

翻译打印收藏纠错

作者： Zeyu,Zhang ^[1] ; Chunlei,Liu ^[2] ; Yongyi,Bai ^[3] ; Xin,Li ^[2] ; Xiaojian,Gao ^[4] ; Chen,Li ^[3] ; Ge,Guo ^[2] ; Si,Chen ^[4] ; Mingzhuang,Sun ^[1] ; Kang,Liu ^[2] ; Yang,Li ^[4] ; Kunlun,He ^[2]

作者单位： Medical Big Data Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing, China. ^[1] Beijing Key Laboratory of Chronic Heart Failure Precision Medicine, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing, China. ^[2] Department of Cardiology, The Second Medical Center of Chinese PLA General Hospital, Beijing, China. ^[3] Translational Medicine Research Center, Medical Innovation Research Division of Chinese PLA General Hospital, Beijing, China. ^[4] Senior Department of Cardiology, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China. ^[5]

关键词 Endothelin (ET-1)Pipersentan endothelin receptor antagonist macitentan pulmonary hypertension

DOI 10.3389/fphar.2022.920222

PMID 35795553

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2022年13卷

920222页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pipersentan: A De Novo Synthetic Endothelin Receptor Antagonist that Inhibits Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除